- Metronomic oral vinorelbine (MOV) is an active and well-tolerated chemotherapy for metastatic NSCLC.
Why this matters
- Previous studies evaluating MOV for treating metastatic NSCLC were limited by small sample sizes.
- Patient-level meta-analysis of 9 studies involving 418 patients (mean age, 72.8±9.1 years; 79.2% male) receiving oral vinorelbine 30-50 mg thrice weekly.
- Most (82.1%) had a stage IV disease; 80% had 1-4 frailty characteristics.
- Funding: Pierre Fabre Oncology.
- Median OS was 8.7 (95% CI, 7.6-9.5) months.
- OS after starting vinorelbine was 64% at 6 months, 30.3% at 1 year, and 8.9% at 2 years.
- Median PFS was 4.2 (95% CI, 3.9-5) months.
- PFS was 35% at 6 months and 11.9% at 1 year.
- No toxicity was reported in 40% of patients; 15.8% experienced grade 3-4 toxicity.
Studies included in the analysis had small sample sizes and different follow-up schedules.